TIMM17A

Across TCGA pan-cancer cohorts, TIMM17A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TIMM17A data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TIMM17A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TIMM17A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and LGG are the cancer types where TIMM17A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.229	0.813	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.629	.027	10	view →
LGG	OS	Median	All	0.294	0.811	.004	6	view →
HNSC	OS	Median	All	0.187	0.685	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TIMM17A–LUAD (DFS)

Open the LUAD breakdown →